Vasoactive Peptides

Many vasoactive peptides induce vasodilation
by acting via specific G-protein coupled receptors
(GPCR). Drug development targets these recep-
tors, as well as the enzymes that generate vasoac-
tive peptides, as a means to gain control over this
process as a potential treatment route of hyperten-
sion. Since its discovery by Yanagisawa in 1988, en-
dothelin-1 (ET-1) has been consistently described
as the most potent vasoconstrictor yet discovered.
Specific antagonists to Endothelin A and B re-
ceptors are well-known and include BQ-123, BQ-
610, and BQ-788. At the present time, urotensin
(U II) is being considered the new endothelin by
many due to its ultrapotent vasoconstrictive prop-
erties. Recently, Patacchini et al. introduced Uran-
tideTM as a potent U II antagonist, the first reported
of its kind. The importance of ET-1 and urotensin
as cardiovascular and renal peptides in humans is
well established, making these peptides and their
antagonists highly important research tools.

CODE PRODUCT QTY

Endothelin Related Products
1 mg
PED-3739-PI Big Endothelin-3 (Human, 1-41 Amide)
5 mg
0.1 mg
PED-4198-s Endothelin-1 (Human)
vial
0.1 mg
PED-4360-s Endothelin-1 (1-31) (Human)
vial
BQ-123 Sodium Salt 1 mg
PED-3512-PI
Endothelin Antagonist 5 mg
BQ-610 1 mg
PED-3610-PI
ETA-Selective Antagonist 5 mg

BQ-788 Sodium Salt 1 mg

PED-3788-PI
ETB-Selective Antagonist 5 mg

Urotensin II is one of the most potent vasoconstrictors known, and Urantide has been reported to be the most
potent antagonist of urotensin II - until now.1,2 Recent studies replacing the Asp amino acid in Urantide led to the
discovery of a new urotensin II antagonist, H-Tic-[Pen-Phe-d-Trp-Orn-Tyr-Cys]-Val-OH. It was found to be more
potent than Urantide at inducing contractions in isolated rat thoracic aorta, with a pA2 value of 9.0 compared to
a pA2 value of 8.3 for Urantide.3
Urotensins - Potent Vasoconstrictors

PUT-4365-v Urotensin II (Human) 0.5 mg vial

PUT-4371-v Urotensin II (Rat) 0.5 mg vial

PUT-4408-v Urotensin II-Related Peptide (Human, Rat) 0.5 mg vial
Endogenous Ligand for U-II Rat Receptor

Peptides International, Inc. P.O. Box 99703 Phone: 502-266-8787 1-800-777-4779

Louisville, KY 40269-0703 USA Fax: 502-267-1329 E-mail: peptides@pepnet.com
 Vasoactive
Peptides
CODE PRODUCT QTY
PUT-3639-PI UrantideTM 1 mg
H-Asp-[Pen-Phe-D-Trp-Orn-Tyr-Cys]-Val-OH
Potent Urotensin II Antagonist
This product is sold under exclusive license.
PUT-3640-PI H-Asp-[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 1 mg
Potent Urotensin II Agonist
This product is sold under exclusive license.
PUT-3928-PI H-Tic-[Pen-Phe-D-Trp-Orn-Try-Cys]-Val-OH 1 mg
Potent Urotensin II Antagonist
This product is sold under exclusive license
1. R.S. Ames, et al., Nature, 401, 282 (1999). 2. R. Patacchini, et al., Br. J. Pharmacol., 140, 1155 (2003). 3. Patent N. FI2007A000032. Patent N. FI2006A000340

Alarin
In 2007, Alarin peptide was identified in human neuroblastic tumors1 and later in mouse. Its name is based on the N-terminal
Ala and the C-terminal Ser residues in the primary structure of a splicing variant of galanin-like peptide (GALP, PGL-4391-s).
Alarin mRNA was found to be present in murine brain, thymus, and skin. In contrast to GALP, alarin has no homology
to galanin. Alarin immunoreactivity was detected in pericytes and venules in human dermis, but not in endothelial cells
of blood vessels.2 Alarin inhibits substance P and CGRP activated inflammatory edema formation in picomolar range in
mouse, dose-dependently, which is a characteristic feature also observed with galanin and GALP. The physiological effects
of alarin do not appear to be mediated via the known galanin receptors. Further studies should clarify the receptor type and
physiological activity of alarin.
PAL-4449-s Alarin 0.1 mg
Ala-Pro-Ala-His-Arg-Ser-Ser-Thr-Phe-Pro-Lys-Trp-Val-Thr-Lys-Thr-Glu-Arg- vial
Gly-Arg-Gln-Pro-Leu-Arg-Ser
APAHRSSTFPKWVTKTERGRQPLRS
(M.W. 2894.30) C127H205N43O35
Vasoactive Peptide / Splice Variant of Galanin-Like Peptide
Synthetic Product
R. Lang, et al., Pharmacol. Ther., 115, 177 (2007). (Review)
R. Santic, et al., J. Mol. Neurosci., 29, 145 (2006). (Original)
R. Santic, et al., Proc. Natl. Acad. Sci. U.S.A., 104, 10217 (2007). (Pharmacol.)

1. R. Santic, et al., J. Mol. Neurosci., 29, 145 (2006). (Original)

2. R. Santic, et al., Proc. Natl. Acad. Sci. U.S.A., 104, 10217 (2007). (Pharmacol.)

Other Vasoactive Peptides

VAS-3878-PI [Arg8]-Vasopressin 1 mg
H-[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Arg-Gly-NH2 5 mg
(M.W. 1084.25) C46H65N15O12S2 [113-79-1]
Peptide Antidiuretic Hormone Originating from Hypothalamus; Plays Role in
Osmolalit
T. Tsuji, et al., J. Physiol., 10.1113/JP274025 On-line acceptance 4-12-17.
P.J.Duncan, et al., J. Physiol., 593, 1197 (2015).
F.Jean-Alphonse, et al., J. Biol. Chem., 289, 3960 (2014).
C.Y.Jiang, et al., J. Neurophysiol., 111, 991 (2014).

Peptides International, Inc. P.O. Box 99703 Phone: 502-266-8787 1-800-777-4779

Louisville, KY 40269-0703 USA Fax: 502-267-1329 E-mail: peptides@pepnet.com